Follow the molecule — GLP-1 drugs, gene therapy, robotic surgery, and digital health are rewriting the economics of human lifespan.
Published by @AIccelerateEng
The data powering the longevity revolution — real numbers, current as of Q4 2025 / Q1 2026.
Full-year 2025 revenue by ticker — the scale of the longevity economy.
Follow the molecule — from drug discovery through gene therapy to digital care delivery.
Financials, thesis, and catalysts for each position in the longevity value chain.
The GLP-1 category king. Lilly's dual-mechanism tirzepatide (targeting GLP-1 + GIP) has demonstrated clinical superiority over Novo's single-acting semaglutide, translating to 60%+ U.S. market share. Mounjaro + Zepbound combined for $36.5B — now the world's best-selling drug franchise. Oral GLP-1 pill orforglipron pending mid-2026 approval removes the injection barrier for hundreds of millions of potential patients. $27B invested in four new U.S. manufacturing facilities.
The GLP-1 pioneer under pressure. Novo created the category with Ozempic and Wegovy but is ceding share to Lilly's superior dual-mechanism tirzepatide. At ~$165B vs. Lilly's ~$860B, Novo trades at a fraction of its rival despite $34.6B in semaglutide revenue. Oral Wegovy launched Jan 2026. CagriSema (semaglutide + amylin dual-agonist) is the counter-offensive. Recovery trade offers significant upside if execution improves. Risk of continued share loss is real.
The razor-and-blades model perfected. 11,106 da Vinci systems installed globally create an annuity stream — 84% of revenue is recurring from instruments, accessories, and service. The da Vinci 5 upgrade cycle is accelerating (870 placed in 2025 vs. 362 in 2024). 3.15 million procedures in 2025 (+18% YoY). As humans live longer, they need more surgeries, and those surgeries are increasingly robotic. 80%+ market share in surgical robotics.
From CF dominance to the cure economy. Vertex owns the cystic fibrosis market (~$10B from Trikafta/Kaftrio) and is now diversifying into gene therapy via Casgevy — the world's first approved CRISPR therapy. Casgevy cures sickle cell disease and beta thalassemia. $116M in 2025 revenue, accelerating (Q4 beat: $54M vs. $38M expected). Non-CF portfolio targeted at $500M in 2026 (185% increase). Pipeline includes renal disease, pain (Journavx), and expanded CF age groups.
The underappreciated Dupixent machine. Dupixent is the world's #1 Type 2 inflammation drug with 8 approved indications and 1.4M+ patients. Q4 2025 global sales hit $4.9B (+32% YoY). Regeneron's Sanofi profit share grew 42% in Q4. Critical inflection: Sanofi development balance (~$600M remaining) expected fully repaid by mid-2026, unlocking higher profit participation. At ~$78B market cap, the most reasonably valued name in this basket. Oncology diversification via Libtayo + Lynozyfic.
The highest-risk, highest-reward turnaround bet. The global telehealth market is projected to reach $455B by 2030 (24.7% CAGR), yet the category leader trades at 0.4x sales with a $950M market cap. Integrated Care growing modestly, BetterHelp declining. Operational turnaround underway — Q4 EBITDA margin improved to 13%. Serves 97–100M U.S. members. At this valuation, either a buyout target or a value trap. Not for the faint-hearted.
Positioning each ticker by risk profile and potential reward — size indicates conviction level.
Key events and milestones that could move these stocks in 2026 and beyond.